Olivia Aranha, MD
Medical Oncology · Saint Louis, MONPI 1386841211
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $10,150 of the $12,434 with a category attached, or 81.6%. Seagen Inc. accounts for 90.8% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2023 at $11,291 and has fallen 94.7% since, to $599 in 2025.
Across 24 payments — averaging $518.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Seagen Inc.$11K
- AstraZeneca$370
- Astrazeneca UK Limited$174
- Array Biopharma Inc$139
- Amgen$123
- Ipsen Biopharmaceuticals, Inc$113
- plus $223 from 5 others
Across 7 payments — averaging $41,480 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$244K
- Ipsen Bioscience Inc.$24K
- Pfizer$23K
What the payments were for
- Consulting fees$10,15082%
- Travel & lodging$1,0518%
- Food & beverage$1,19910%
- Education$340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Seagen Inc. | 7 | $11,291 |
| AstraZeneca | 4 | $370 |
| Astrazeneca UK Limited | 4 | $174 |
| Array Biopharma Inc | 1 | $139 |
| Amgen | 1 | $123 |
| Ipsen Biopharmaceuticals, Inc | 1 | $113 |
| Janssen Scientific Affairs, LLC | 1 | $104 |
| Beone Medicines USA, Inc. | 1 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Clovis Oncology, Inc. | 2 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,434 in reported general payments places this provider in the 65th percentile of 144 medical oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 61 | $46,800 |
| CreonLipase/Protease/Amylase | 23 | $38,885 |
| Prochlorperazine Maleate | 97 | $3,063 |
| LoperamideLoperamide Hcl | 66 | $1,392 |
| Dexamethasone | 96 | $1,118 |
| Oxycodone Hcl | 53 | $827 |
| Lidocaine Hcl ViscousLidocaine Hcl | 33 | $639 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 46 | $552 |
| Ondansetron Hcl | 69 | $545 |
| Lidocaine-PrilocaineLidocaine/Prilocaine | 37 | $514 |
| Minocycline Hcl | 13 | $481 |
| Gabapentin | 44 | $454 |
| Tramadol Hcl | 12 | $431 |
| Pantoprazole Sodium | 31 | $413 |
| Ondansetron OdtOndansetron | 18 | $372 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Saint Louis
- Brad KahlSaint Louis$336K
- Russell PachynskiSaint Louis$226K
- Mark SchroederSaint Louis$198K
- George AnsstasSaint Louis$189K
- Ravi VijSaint Louis$153K
- Douglas AdkinsSaint Louis$141K
- Milan ChhedaSaint Louis$105K
- Maurice WillisSaint Louis$101K
- Moh'd KhushmanSaint Louis$84K
- Camille AbboudSaint Louis$70K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.